Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Whitehawk Therapeutics (WHWK) Operating Expenses (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Operating Expenses for 8 consecutive years, with $19.5 million as the latest value for Q3 2025.

  • On a quarterly basis, Operating Expenses fell 5.23% to $19.5 million in Q3 2025 year-over-year; TTM through Sep 2025 was $122.8 million, a 34.56% increase, with the full-year FY2024 number at $93.4 million, down 2.96% from a year prior.
  • Operating Expenses was $19.5 million for Q3 2025 at Whitehawk Therapeutics, down from $54.7 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $87.3 million in Q3 2021 to a low of $3.9 million in Q2 2021.
  • A 5-year average of $25.1 million and a median of $21.8 million in 2022 define the central range for Operating Expenses.
  • Peak YoY movement for Operating Expenses: soared 1846.72% in 2021, then plummeted 77.92% in 2022.
  • Whitehawk Therapeutics' Operating Expenses stood at $16.9 million in 2021, then rose by 22.15% to $20.7 million in 2022, then grew by 16.14% to $24.0 million in 2023, then rose by 8.94% to $26.2 million in 2024, then decreased by 25.36% to $19.5 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Operating Expenses are $19.5 million (Q3 2025), $54.7 million (Q2 2025), and $22.4 million (Q1 2025).